Review of the latest local treatments for uveitis

References

• Darrell RW, Wagner HP, Kurland LT. Epidemiology of uveitis: incidence and prevalence in a small urban community. Arch Ophthalmol 1962;68:502-14
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB. The natural history of uveitis. Int Ophthalmol 1990;14:303-8
   PubMed Web of Science ®Google Scholar
• Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996;80:844-8
   PubMed Web of Science ®Google Scholar
• Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111(3):491-500
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lloyd MJ, Choi D, et al. Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol 2008;146(6):890-6
   PubMed Web of Science ®Google Scholar
• Acharya NR, Tham VM, Esterberg E, et al. Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. JAMA Ophthalmol 2013;131(11):1405-12
   PubMed Web of Science ®Google Scholar
• Taylor HR, Keeffe JE. World blindness: a 21st century perspective. Br J Ophthalmol 2001;85:261-6
   PubMed Web of Science ®Google Scholar
• Durrani OM, Tehrani NN, Marr JE, et al. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 2004;88:1159-62
   PubMed Web of Science ®Google Scholar
• Smit RL, Baarsma S, de Vries J. Classification of 750 consecutive uveitis patients in the Rotterdam Eye Hospital. Int Ophthalmol 1993;17:71-5
   PubMed Web of Science ®Google Scholar
• Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin 2005;45(2):1-13. Review
   PubMedGoogle Scholar
• Rothova A, Suttorp-van Schulten MSA, Treffers WF, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-6
   PubMed Web of Science ®Google Scholar
• Bringmann A, Reichenbach A, Wiedemann P. Pathomechanisms of cystoid macular edema. Ophthalmic Res 2004;36(5):241-9; Review
   PubMed Web of Science ®Google Scholar
• Scholl S, Augustin A, Loewenstein A, et al. General pathophysiology of macular edema. Eur J Ophthalmol 2011;21(Suppl 6):S10-19
   PubMed Web of Science ®Google Scholar
• Coscas G, Gaudric A. Natural course of nonaphakic cystoid macular edema. Surv Ophthalmol 1984;28(Suppl):471-84
   PubMedGoogle Scholar
• Bentley CR, Stanford MR, Shilling JS, et al. Macular ischaemia in posterior uveitis. Eye (Lond) 1993;7(Pt 3):411-14
   PubMedGoogle Scholar
• Hikichi T, Trempe CL. Role of the vitreous in the prognosis of peripheral uveitis. Am J Ophthalmol 1993;116(4):401-5
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Kaufman SC, Palestine AG, et al. Macular thickening and visual acuity. Measurement in patients with cystoid macular edema. Ophthalmology 1987;94(9):1134-9
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Callanan D, Dugel P, et al. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina 2006(Suppl):1-16
   PubMed Web of Science ®Google Scholar
• Yasukawa T, Ogura Y, Sakurai E, et al. Intraocular sustained drug delivery using implantable polymeric devices. Adv Drug Deliv Rev 2005;57(14):2033-46
   PubMed Web of Science ®Google Scholar
• Schimmer BP, Funder JW. ACTH, adrenal steroids, and pharmacology of the adrenal cortex. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gillman’s the pharmacological basis of therapeutics, 12e. McGraw-Hill; New York, NY, USA: 2011. Available from: http://accessmedicine.mhmedical.com/content.aspx?bookid=374&Sectionid=41266251. [Accessed 20 August 2014]
   Google Scholar
• Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113(6):1020-7
   PubMed Web of Science ®Google Scholar
• Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008;126:1191-201
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007;125:1478-85
   PubMed Web of Science ®Google Scholar
• Pavesio C, Zierhut M, Bairi K, Fluocinolone Acetonide Study Group. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010;117(3):567-75, 575.e1
   PubMed Web of Science ®Google Scholar
• Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011;118:1916-26
   PubMed Web of Science ®Google Scholar
• Nicholson BP, Singh RP, Sears JE, et al. Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery. Am J Ophthalmol 2012;154(6):969-973.e1
   PubMed Web of Science ®Google Scholar
• Akduman L, Cetin EN, Levy J, et al. Spontaneous dissociation and dislocation of Retisert pellet. Ocul Immunol Inflamm 2013;21(1):87-9
   PubMed Web of Science ®Google Scholar
• Taban M, Lowder CY, Ventura AA, et al. Scleral thickness following fluocinolone acetonide implant (Retisert). Ocul Immunol Inflamm 2010;18(4):305-13
   PubMed Web of Science ®Google Scholar
• Taban M, Lowder CY, Kaiser PK. Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis. Retina 2008;28(9):1280-8
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-17
   PubMed Web of Science ®Google Scholar
• Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009;147:1048-54; e1-2
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-53
   PubMed Web of Science ®Google Scholar
• Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52:80-6
   PubMed Web of Science ®Google Scholar
• Saraiya NV, Patel SS, Goldstein DA. A report of high intraocular pressure with the dexamethasone intravitreal implant. Arch Ophthalmol 2011;129:1638-9; author reply 1639-40
   PubMedGoogle Scholar
• Meyer LM, Schonfeld CL. Secondary glaucoma after intravitreal dexamethasone 0.7 mg implant in patients with retinal vein occlusion: a one-year follow-up. J Ocul Pharmacol Ther 2013;29:560-5
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Cerón OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Dexamethasone implant) intravitreal implants in uveitis. J Ocul Pharmacol Ther 2013;29(5):501-7
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of an injectable fluocinolone acetonide intravitreal insert. Available from: www.clinicaltrials.gov/show/NCT01694186
   Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119(10):2125-32
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Hafiz G, Shah SM, Famous Study Group. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117(7):1393-9.e3
   PubMed Web of Science ®Google Scholar
• Krohn J, Bertelsen T. Corrosion casts of the suprachoroidal space and uveoscleral drainage routes in the human eye. Acta Ophthalmol Scand 1997;75(1):32-5
   PubMedGoogle Scholar
• Einmahl S, Savoldelli M, D’Hermies F, et al. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest Ophthalmol Vis Sci 2002;43(5):1533-9
   PubMed Web of Science ®Google Scholar
• Olsen TW, Feng X, Wabner K, et al. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am J Ophthalmol 2006;142(5):777-87
   PubMed Web of Science ®Google Scholar
• Gilger BC, Abarca EM, Salmon JH, Patel S. Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles. Invest Ophthalmol Vis Sci 2013;54(4):2483-92
   PubMed Web of Science ®Google Scholar
• Safety study of suprachoroidal triamcinolone acetonide via microneedle to treat uveitis. Available from: www.clinicaltrials.gov/show/NCT01789320
   Google Scholar
• Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948;238(23):787-93
   PubMed Web of Science ®Google Scholar
• Hertz R, Lewis J Jr, Lipsett MB. Five year’s experience with the chemotherapy of metastatic choriocarcinoma and related trophoblastic tumors in women. Am J Obstet Gynecol 1961;82:631-40
   PubMed Web of Science ®Google Scholar
• Hersh EM, Carbone PP, Wong VG, Freireich EJ. Inhibition of the primary immune response in man by anti-metabolites. Cancer Res 1965;25(7):997-1001
   PubMedGoogle Scholar
• Mehta PJ, Alexander JL, Sen HN. Pediatric uveitis: new and future treatments. Curr Opin Ophthalmol 2013;24(5):453-62
   PubMed Web of Science ®Google Scholar
• Chabner BA, Bertino J, Cleary J, et al. Cytotoxic agents. Chemotherapy of neoplastic diseases. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gillman’s the pharmacological basis of therapeutics. McGraw-Hill; New York, NY, USA: 2011
   Google Scholar
• Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997;115:1152-6
   PubMed Web of Science ®Google Scholar
• Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002;109(9):1709-16
   PubMed Web of Science ®Google Scholar
• Hardwig PW, Pulido JS, Erie JC, et al. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol 2006;142:883-5
   PubMed Web of Science ®Google Scholar
• Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009;116:797-801
   PubMed Web of Science ®Google Scholar
• Taylor SR, Banker A, Schlaen A, et al. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina 2013;33(10):2149-54
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82
   PubMed Web of Science ®Google Scholar
• Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004;22:657-82
   PubMed Web of Science ®Google Scholar
• Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-73
   PubMedGoogle Scholar
• Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994;153:4159-68
   PubMed Web of Science ®Google Scholar
• Vinores SA, Chan CC, Vinores MA, et al. Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol 1998;89:43-50
   PubMed Web of Science ®Google Scholar
• Fine HF, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001;132:794-6
   PubMed Web of Science ®Google Scholar
• Cohen T, Nahari D, Cerem LW, et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271(2):736-41
   PubMed Web of Science ®Google Scholar
• van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol 2006;142(1):192-4
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007;114(8):1574-1579.e1
   PubMed Web of Science ®Google Scholar
• Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 2008;28(1):41-5
   PubMed Web of Science ®Google Scholar
• Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009;148(2):303-9. e2
   PubMed Web of Science ®Google Scholar
• Baxter SL, Pistilli M, Pujari SS, et al. Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol 2013;156(3):468-77
   PubMed Web of Science ®Google Scholar
• Kuo IC, Cunningham ET Jr. Ocular neovascularization in patients with uveitis. Int Ophthalmol Clin 2000;40(2):111-26; Review
   PubMedGoogle Scholar
• Lott MN, Schiffman JC, Davis JL. Bevacizumab in inflammatory eye disease. Am J Ophthalmol 2009;148(5):711-17
   PubMed Web of Science ®Google Scholar
• Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit 2001;23:559-86
   PubMed Web of Science ®Google Scholar
• Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335-40
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Ibrahim MA, Watters A, et al. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect 2013;3(1):32
   PubMedGoogle Scholar
• Sirolimus as therapeutic approach to uveitis (SAVE). Available from: http://clinicaltrials.gov/show/NCT00908466
   Google Scholar
• Intravitreal sirolimus as therapeutic approach to uveitis (SAVE-2). Available from: http://clinicaltrials.gov/show/NCT01280669
   Google Scholar
• Subconjunctival sirolimus for the treatment of autoimmune active anterior uveitis. Available from: http://clinicaltrials.gov/show/NCT00876434
   Google Scholar
• Rush RB, Goldstein DA, Callanan DG, et al. Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device. Am J Ophthalmol 2011;151(4):630-6
   PubMed Web of Science ®Google Scholar